AbbVie and Allergan announced Tuesday, March 17, that they signed a consent decree with the US Federal Trade Commission that will commit the companies to selling some properties if they commence a planned merger.
As previously announced, the companies plan to sell brazikumab, an experimental Crohn’s disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé.
Tuesday’s announcement also stated that Nestlé plans to purchase Viokace, a similar product. The companies stated they expect the deal to close in May.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
U.K. Data Bill Still Facing Opposition Ahead of Final Vote
May 1, 2025 by
CPI
UK Watchdog Eyes Reform of £2bn Veterinary Sector Amid Price Hikes
May 1, 2025 by
CPI
Cargill Reaches Settlement with McDonald’s in Beef Price-Fixing Suit
May 1, 2025 by
CPI
Advertising Enters the Chat: Google Integrates Ads Into AI
May 1, 2025 by
CPI
House Judiciary Committee Backs Away from Bid to Strip FTC’s Antitrust Power
May 1, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece